JSM Activity #211

This is the preliminary program for the 2003 Joint Statistical Meetings in San Francisco, California. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 2-5, 2003); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2003 Program page
Legend: = Applied Session, = Theme Session, = Presenter
Hotels: H = Hilton San Francisco, R = Reniassance Parc Hotel 55, N = Nikko San Francisco
Add To My Program
211 Applied Session Tue, 8/5/03, 8:30 AM - 10:20 AM R-Parc Ballroom I
Pharmacokinetics and Pharmacodynamics - Contributed - Papers
Biopharmaceutical Section
Chair(s): Deborah L. Panebianco, Merck & Co.
     8:35 AM   Optimal Designs for Population PK/PD Models with Serial Sampling — Sergei Leonov, GlaxoSmithKline; Robert C. Gagnon, GlaxoSmithKline
     8:50 AM   Using Nonlinear Mixed Models for Pediatric PK Studies — Alan H. Hartford, North Carolina State University; Arturo Porras, Merck Research Laboratories; Elizabeth Migoya, Merck Research Laboratories; Ji Zhang, Merck Research Laboratories
     9:05 AM   The Distribution of Half-Life and Its Median — Li-Wen Xi, Merck & Co., Inc.
     9:20 AM   Statistical Approaches to the Analysis of Effects of Renal Impairment on Pharmacokinetics of Drugs — Robert A. Smith, Bristol-Myers Squibb Company
     9:35 AM   Estimating Pharmaceutical Conditions Under Which a Mean is Large — Jennifer L. S. Gauvin, North Carolina State University & Roche Palo Alto; Roger L. Berger, North Carolina State University & NSF
     9:50 AM   Bayesian Dose Individualization in Anticancer Transplant Therapy — Gary L. Rosner, University of Texas M.D. Anderson Cancer Center; Feng Tang, University of Texas M.D. Anderson Cancer Center; Peter Mueller, University of Texas M.D. Anderson Cancer Center
     10:05 AM   QoL in Oncology: A Review of Several Models in the Area Under the Curve Analysis — Alexia Iasonos, Bristol-Myers Squibb Company; Tai-Tsang Chen, Bristol-Myers Squibb Company; Antonella Maniero, Bristol-Myers Squibb Company; Jan Bogaerts, Bristol-Myers Squibb Company
 

JSM 2003 For information, contact meetings@amstat.org or phone (703) 684-1221. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2003